Mesenchymal stromal cells and chronic inflammatory bowel disease

Immunology Letters

Volumn 168, Issue 2, 2015, Pages 191-200

  Algeri, M ^a   Conforti, A ^a   Pitisci, A ^a   Starc, N ^a,c   Tomao, L ^a   Bernardo, M E ^a   Locatelli, F ^a,b  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Cell therapy; Crohn's disease; Inflammatory bowel disease; Mesenchymal stromal cells; Regenerative medicine; Translational research; Ulcerative colitis

Indexed keywords

CD4 ANTIGEN; CD45RB ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 22; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; ARTICLE; CD4+ T LYMPHOCYTE; CELL REGENERATION; CELL THERAPY; CHRONIC DISEASE; CLINICAL EFFECTIVENESS; CROHN DISEASE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE MODEL; ENVIRONMENTAL FACTOR; EVIDENCE BASED MEDICINE; GENETIC SUSCEPTIBILITY; IMMUNOMODULATION; IMMUNOTHERAPY; INFLAMMATORY BOWEL DISEASE; INNATE IMMUNITY; LUMINAL INFLAMMATORY BOWEL DISEASE; MESENCHYMAL STROMA CELL; MUCOSAL IMMUNITY; OUTCOME ASSESSMENT; PATIENT SAFETY; PERIANAL FISTULIZING CROHN DISEASE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; ANIMAL; CELL MOTION; CLINICAL TRIAL (TOPIC); CYTOLOGY; HUMAN; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASES; MESENCHYMAL STEM CELL TRANSPLANTATION; PROCEDURES; TREATMENT OUTCOME;

ADAPTIVE IMMUNITY; ANIMALS; CELL MOVEMENT; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNITY, INNATE; INFLAMMATORY BOWEL DISEASES; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; TREATMENT OUTCOME;

EID: 84949623553     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2015.06.018     Document Type: Article

References (118)

1. Kappelman M.D., Rifas-Shiman S.L., Porter C.Q., Ollendorf D.A., Sandler R.S., Galanko J.A., et al. Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults. Gastroenterology 2008, 135:1907-1913.
2. Abraham C., Cho J.H. Inflammatory bowel disease. N. Engl. J. Med. 2009, 361:2066-2078.
3. Kaser A., Zeissig S., Blumberg R.S. Inflammatory bowel disease. Annu. Rev. Immunol. 2010, 28:573-621.
4. Baumgart D.C., Sandborn W.J. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 2007, 369:1641-1657.
5. Bernstein C.N. Treatment of IBD: where we are and where we are going. Am. J. Gastroenterol. 2015, 110:114-126.
6. Kamm M.A., Ng S.C. Perianal fistulizing Crohn's disease: a call to action. Clin. Gastroenterol. Hepatol.: Off. Clin. Pract. J. Am. Gastroenterol. Assoc. 2008, 6:7-10.
7. Bernardo M.E., Pagliara D., Locatelli F. Mesenchymal stromal cell therapy: a revolution in regenerative medicine?. Bone Marrow Transplant. 2012, 47:164-171.
8. Friedenstein A.J., Chailakhyan R.K., Latsinik N.V., Panasyuk A.F., Keiliss-Borok I.V. Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues. Cloning in vitro and retransplantation in vivo. Transplantation 1974, 17:331-340.
9. Campagnoli C., Roberts I.A., Kumar S., Bennett P.R., Bellantuono I., Fisk N.M. Identification of mesenchymal stem/progenitor cells in human first-trimester fetal blood, liver, and bone marrow. Blood 2001, 98:2396-2402.
10. Im G.I., Shin Y.W., Lee K.B. Do adipose tissue-derived mesenchymal stem cells have the same osteogenic and chondrogenic potential as bone marrow-derived cells?. Osteoarthritis Cartilage/OARS, Osteoarthritis Res. Soc. 2005, 13:845-853.
11. Barry F.P., Murphy J.M. Mesenchymal stem cells: clinical applications and biological characterization. Int. J. Biochem. Cell Biol. 2004, 36:568-584.
12. Quarto R., Mastrogiacomo M., Cancedda R., Kutepov S.M., Mukhachev V., Lavroukov A., et al. Repair of large bone defects with the use of autologous bone marrow stromal cells. N. Engl. J. Med. 2001, 344:385-386.
13. Haleem A.M., Singergy A.A., Sabry D., Atta H.M., Rashed L.A., Chu C.R., et al. The clinical use of human culture-expanded autologous bone marrow mesenchymal stem cells transplanted on platelet-rich fibrin glue in the treatment of articular cartilage defects: a pilot study and preliminary results. Cartilage 2010, 1:253-261.
14. Ball L.M., Bernardo M.E., Roelofs H., Lankester A., Cometa A., Egeler R.M., et al. Cotransplantation of ex vivo expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation. Blood 2007, 110:2764-2767.
15. Bernardo M.E., Ball L.M., Cometa A.M., Roelofs H., Zecca M., Avanzini M.A., et al. Co-infusion of ex vivo-expanded, parental MSCs prevents life-threatening acute GVHD, but does not reduce the risk of graft failure in pediatric patients undergoing allogeneic umbilical cord blood transplantation. Bone Marrow Transplant. 2011, 46:200-207.
16. Ball L.M., Bernardo M.E., Roelofs H., van Tol M.J., Contoli B., Zwaginga J.J., et al. Multiple infusions of mesenchymal stromal cells induce sustained remission in children with steroid-refractory, grade III-IV acute graft-versus-host disease. Br. J. Haematol. 2013, 163:501-509.
17. Jurewicz M., Yang S., Augello A., Godwin J.G., Moore R.F., Azzi J., et al. Congenic mesenchymal stem cell therapy reverses hyperglycemia in experimental type 1 diabetes. Diabetes 2010, 59:3139-3147.
18. Kunter U., Rong S., Boor P., Eitner F., Muller-Newen G., Djuric Z., et al. Mesenchymal stem cells prevent progressive experimental renal failure but maldifferentiate into glomerular adipocytes. J. Am. Soc. Nephrol. 2007, 18:1754-1764.
19. Morigi M., Benigni A. Mesenchymal stem cells and kidney repair. Nephrol. Dial. Transplant.: Off. Publ. Eur. Dial. Transpl. Assoc. - Eur. Ren. Assoc. 2013, 28:788-793.
20. Hofstetter C.P., Schwarz E.J., Hess D., Widenfalk J., El Manira A., Prockop D.J., et al. Marrow stromal cells form guiding strands in the injured spinal cord and promote recovery. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:2199-2204.
21. Honma T., Honmou O., Iihoshi S., Harada K., Houkin K., Hamada H., et al. Intravenous infusion of immortalized human mesenchymal stem cells protects against injury in a cerebral ischemia model in adult rat. Exp. Neurol. 2006, 199:56-66.
22. Gonzalez M.A., Gonzalez-Rey E., Rico L., Buscher D., Delgado M. Adipose-derived mesenchymal stem cells alleviate experimental colitis by inhibiting inflammatory and autoimmune responses. Gastroenterology 2009, 136:978-989.
23. Gupta N., Su X., Popov B., Lee J.W., Serikov V., Matthay M.A. Intrapulmonary delivery of bone marrow-derived mesenchymal stem cells improves survival and attenuates endotoxin-induced acute lung injury in mice. J. Immunol. 2007, 179:1855-1863.
24. Lee R.H., Pulin A.A., Seo M.J., Kota D.J., Ylostalo J., Larson B.L., et al. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell 2009, 5:54-63.
25. Parekkadan B., van Poll D., Suganuma K., Carter E.A., Berthiaume F., Tilles A.W., et al. Mesenchymal stem cell-derived molecules reverse fulminant hepatic failure. PLoS ONE 2007, 2:e941.
26. Geremia A., Biancheri P., Allan P., Corazza G.R., Di Sabatino A. Innate and adaptive immunity in inflammatory bowel disease. Autoimmun. Rev. 2014, 13:3-10.
27. Cho J.H. The genetics and immunopathogenesis of inflammatory bowel disease. Nat. Rev. Immunol. 2008, 8:458-466.
28. Hampe J., Franke A., Rosenstiel P., Till A., Teuber M., Huse K., et al. A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat. Genet. 2007, 39:207-211.
29. Parkes M., Barrett J.C., Prescott N.J., Tremelling M., Anderson C.A., Fisher S.A., et al. Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn's disease susceptibility. Nat. Genet. 2007, 39:830-832.
30. Franke A., McGovern D.P., Barrett J.C., Wang K., Radford-Smith G.L., Ahmad T., et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat. Genet. 2010, 42:1118-1125.
31. Strober W., Fuss I.J. Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. Gastroenterology 2011, 140:1756-1767.
32. Christophi G.P., Rong R., Holtzapple P.G., Massa P.T., Landas S.K. Immune markers and differential signaling networks in ulcerative colitis and Crohn's disease. Inflamm. Bowel Dis. 2012, 18:2342-2356.
33. Zhou L., Ivanov I.I., Spolski R., Min R., Shenderov K., Egawa T., et al. IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat. Immunol. 2007, 8:967-974.
34. Monteleone I., Sarra M., Pallone F., Monteleone G. Th17-related cytokines in inflammatory bowel diseases: friends or foes?. Curr. Mol. Med. 2012, 12:592-597.
35. Salas A., Panes J. IBD: regulatory T cells for treatment of Crohn's disease. Nat. Rev. Gastroenterol. Hepatol. 2015.
36. Krampera M., Glennie S., Dyson J., Scott D., Laylor R., Simpson E., et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 2003, 101:3722-3729.
37. Tse W.T., Pendleton J.D., Beyer W.M., Egalka M.C., Guinan E.C. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation 2003, 75:389-397.
38. Luz-Crawford P., Kurte M., Bravo-Alegria J., Contreras R., Nova-Lamperti E., Tejedor G., et al. Mesenchymal stem cells generate a CD4+CD25+Foxp3+ regulatory T cell population during the differentiation process of Th1 and Th17 cells. Stem Cell Res. Ther. 2013, 4:65.
39. Rasmusson I., Ringden O., Sundberg B., Le Blanc K. Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation 2003, 76:1208-1213.
40. Meisel R., Zibert A., Laryea M., Gobel U., Daubener W., Dilloo D. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 2004, 103:4619-4621.
41. Chabannes D., Hill M., Merieau E., Rossignol J., Brion R., Soulillou J.P., et al. A role for heme oxygenase-1 in the immunosuppressive effect of adult rat and human mesenchymal stem cells. Blood 2007, 110:3691-3694.
42. Melief S.M., Schrama E., Brugman M.H., Tiemessen M.M., Hoogduijn M.J., Fibbe W.E., et al. Multipotent stromal cells induce human regulatory T cells through a novel pathway involving skewing of monocytes toward anti-inflammatory macrophages. Stem Cells 2013, 31:1980-1991.
43. Burr S.P., Dazzi F., Garden O.A. Mesenchymal stromal cells and regulatory T cells: the Yin and Yang of peripheral tolerance?. Immunol. Cell Biol. 2013, 91:12-18.
44. Duijvestein M., Wildenberg M.E., Welling M.M., Hennink S., Molendijk I., van Zuylen V.L., et al. Pretreatment with interferon-gamma enhances the therapeutic activity of mesenchymal stromal cells in animal models of colitis. Stem Cells 2011, 29:1549-1558.
45. Krampera M. Mesenchymal stromal cell 'licensing': a multistep process. Leukemia 2011, 25:1408-1414.
46. Bernardo M.E., Fibbe W.E. Mesenchymal stromal cells: sensors and switchers of inflammation. Cell Stem Cell 2013, 13:392-402.
47. Nemoto Y., Kanai T., Takahara M., Oshima S., Nakamura T., Okamoto R., et al. Bone marrow-mesenchymal stem cells are a major source of interleukin-7 and sustain colitis by forming the niche for colitogenic CD4 memory T cells. Gut 2013, 62:1142-1152.
48. Spaggiari G.M., Abdelrazik H., Becchetti F., Moretta L. MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MSC-derived prostaglandin E2. Blood 2009, 113:6576-6583.
49. Deng Y., Yi S., Wang G., Cheng J., Zhang Y., Chen W., et al. Umbilical cord-derived mesenchymal stem cells instruct dendritic cells to acquire tolerogenic phenotypes through the IL-6-mediated upregulation of SOCS1. Stem Cells Dev. 2014, 23:2080-2092.
50. Spaggiari G.M., Capobianco A., Becchetti S., Mingari M.C., Moretta L. Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood 2006, 107:1484-1490.
51. Spaggiari G.M., Capobianco A., Abdelrazik H., Becchetti F., Mingari M.C., Moretta L. Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood 2008, 111:1327-1333.
52. Togel F., Hu Z., Weiss K., Isaac J., Lange C., Westenfelder C. Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms. Am. J. Physiol. Ren. Physiol. 2005, 289:F31-F42.
53. Bai L., Lennon D.P., Caplan A.I., DeChant A., Hecker J., Kranso J., et al. Hepatocyte growth factor mediates mesenchymal stem cell-induced recovery in multiple sclerosis models. Nat. Neurosci. 2012, 15:862-870.
54. Wang Y., Chen X., Cao W., Shi Y. Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications. Nat. Immunol. 2014, 15:1009-1016.
55. Sohni A., Verfaillie C.M. Mesenchymal stem cells migration homing and tracking. Stem Cells Int. 2013, 2013:130763.
56. Eggenhofer E., Benseler V., Kroemer A., Popp F.C., Geissler E.K., Schlitt H.J., et al. Mesenchymal stem cells are short-lived and do not migrate beyond the lungs after intravenous infusion. Front. Immunol. 2012, 3:297.
57. Wynn R.F., Hart C.A., Corradi-Perini C., O'Neill L., Evans C.A., Wraith J.E., et al. A small proportion of mesenchymal stem cells strongly expresses functionally active CXCR4 receptor capable of promoting migration to bone marrow. Blood 2004, 104:2643-2645.
58. Ruster B., Gottig S., Ludwig R.J., Bistrian R., Muller S., Seifried E., et al. Mesenchymal stem cells display coordinated rolling and adhesion behavior on endothelial cells. Blood 2006, 108:3938-3944.
59. Ries C., Egea V., Karow M., Kolb H., Jochum M., Neth P. MMP-2, MT1-MMP, and TIMP-2 are essential for the invasive capacity of human mesenchymal stem cells: differential regulation by inflammatory cytokines. Blood 2007, 109:4055-4063.
60. Chinnadurai R., Ng S., Velu V., Galipeau J. Challenges in animal modelling of mesenchymal stromal cell therapy for inflammatory bowel disease. World J. Gastroenterol. 2015, 21:4779-4787.
61. Wirtz S., Neufert C., Weigmann B., Neurath M.F. Chemically induced mouse models of intestinal inflammation. Nat. Protoc. 2007, 2:541-546.
62. Whittem C.G., Williams A.D., Williams C.S. Murine colitis modeling using dextran sulfate sodium (DSS). J. Vis. Exp. 2010.
63. Motavallian-Naeini A., Andalib S., Rabbani M., Mahzouni P., Afsharipour M., Minaiyan M. Validation and optimization of experimental colitis induction in rats using 2,4,6-trinitrobenzene sulfonic acid. Res. Pharm. Sci. 2012, 7:159-169.
64. Kojima R., Kuroda S., Ohkishi T., Nakamaru K., Hatakeyama S. Oxazolone-induced colitis in BALB/C mice: a new method to evaluate the efficacy of therapeutic agents for ulcerative colitis. J. Pharmacol. Sci. 2004, 96:307-313.
65. Powrie F., Leach M.W., Mauze S., Menon S., Caddle L.B., Coffman R.L. Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4+ T cells. Immunity 1994, 1:553-562.
66. Mottet C., Uhlig H.H., Powrie F. Cutting edge: cure of colitis by CD4+CD25+ regulatory T cells. J. Immunol. 2003, 170:3939-3943.
67. Kennedy R.J., Hoper M., Deodhar K., Erwin P.J., Kirk S.J., Gardiner K.R. Interleukin 10-deficient colitis: new similarities to human inflammatory bowel disease. Br. J. Surg. 2000, 87:1346-1351.
68. Tanaka F., Tominaga K., Ochi M., Tanigawa T., Watanabe T., Fujiwara Y., et al. Exogenous administration of mesenchymal stem cells ameliorates dextran sulfate sodium-induced colitis via anti-inflammatory action in damaged tissue in rats. Life Sci. 2008, 83:771-779.
69. Hayashi Y., Tsuji S., Tsujii M., Nishida T., Ishii S., Iijima H., et al. Topical implantation of mesenchymal stem cells has beneficial effects on healing of experimental colitis in rats. J. Pharmacol. Exp. Ther. 2008, 326:523-531.
70. Wei Y., Nie Y., Lai J., Wan Y.J., Li Y. Comparison of the population capacity of hematopoietic and mesenchymal stem cells in experimental colitis rat model. Transplantation 2009, 88:42-48.
71. Yabana T., Arimura Y., Tanaka H., Goto A., Hosokawa M., Nagaishi K., et al. Enhancing epithelial engraftment of rat mesenchymal stem cells restores epithelial barrier integrity. J. Pathol. 2009, 218:350-359.
72. Zhang Q., Shi S., Liu Y., Uyanne J., Shi Y., Shi S., et al. Mesenchymal stem cells derived from human gingiva are capable of immunomodulatory functions and ameliorate inflammation-related tissue destruction in experimental colitis. J. Immunol. 2009, 183:7787-7798.
73. Gonzalez-Rey E., Anderson P., Gonzalez M.A., Rico L., Buscher D., Delgado M. Human adult stem cells derived from adipose tissue protect against experimental colitis and sepsis. Gut 2009, 58:929-939.
74. Liang L., Dong C., Chen X., Fang Z., Xu J., Liu M., et al. Human umbilical cord mesenchymal stem cells ameliorate mice trinitrobenzene sulfonic acid (TNBS)-induced colitis. Cell Transplant. 2011, 20:1395-1408.
75. Li L., Liu S., Xu Y., Zhang A., Jiang J., Tan W., et al. Human umbilical cord-derived mesenchymal stem cells downregulate inflammatory responses by shifting the Treg/Th17 profile in experimental colitis. Pharmacology 2013, 92:257-264.
76. Fan H., Zhao G., Liu L., Liu F., Gong W., Liu X., et al. Pre-treatment with IL-1beta enhances the efficacy of MSC transplantation in DSS-induced colitis. Cell. Mol. Immunol. 2012, 9:473-481.
77. Anderson P., Souza-Moreira L., Morell M., Caro M., O'Valle F., Gonzalez-Rey E., et al. Adipose-derived mesenchymal stromal cells induce immunomodulatory macrophages which protect from experimental colitis and sepsis. Gut 2013, 62:1131-1141.
78. Danese S. New therapies for inflammatory bowel disease: from the bench to the bedside. Gut 2012, 61:918-932.
79. Chinnadurai R., Garcia M.A., Sakurai Y., Lam W.A., Kirk A.D., Galipeau J., et al. Actin cytoskeletal disruption following cryopreservation alters the biodistribution of human mesenchymal stromal cells in vivo. Stem Cell Rep. 2014, 3:60-72.
80. Eliopoulos N., Stagg J., Lejeune L., Pommey S., Galipeau J. Allogeneic marrow stromal cells are immune rejected by MHC class I- and class II-mismatched recipient mice. Blood 2005, 106:4057-4065.
81. Onken J., Gallup D., Hanson J., Pandak M., Custer L. Successful outpatient treatment of refractory Crohn's disease using adult mesenchymal stem cells. American college of Gastroenterology Annual Meeting 2006.
82. Duijvestein M., Vos A.C., Roelofs H., Wildenberg M.E., Wendrich B.B., Verspaget H.W., et al. Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: results of a phase I study. Gut 2010, 59:1662-1669.
83. Lazebnik L.B., Konopliannikov A.G., Kniazev O.V., Parfenov A.I., Tsaregorodtseva T.M., Ruchkina I.N., et al. Use of allogeneic mesenchymal stem cells in the treatment of intestinal inflammatory diseases. Ter. Arkh. 2010, 82:38-43.
84. Kniazev O.V., Parfenov A.I., KO A.G., Ruchkina I.N., Churikova A.A., BykovaF S.V., et al. Safety of mesenchymal stromal cell therapy for inflammatory bowel diseases: results of a 5-year follow-up. Ter. Arkh. 2015, 87:39-44.
85. Liang J., Zhang H., Wang D., Feng X., Wang H., Hua B., et al. Allogeneic mesenchymal stem cell transplantation in seven patients with refractory inflammatory bowel disease. Gut 2012, 61:468-469.
86. Forbes G.M., Sturm M.J., Leong R.W., Sparrow M.P., Segarajasingam D., Cummins A.G., et al. A phase 2 study of allogeneic mesenchymal stromal cells for luminal Crohn's disease refractory to biologic therapy. Clin. Gastroenterol. Hepatol.: Off. Clin. Pract. J. Am. Gastroenterol. Assoc. 2014, 12:64-71.
87. Pfizer, Athersys Inc A Study to Investigate the Safety and Possible Clinical Benefit of Multistem(r) in Patients with Moderate to Severe Ulcerative Colitis 2014.
88. ® Adult Human Stem Cells for Treatment-Resistant Moderate-to-Severe Crohn's Disease 2016.
89. Garcia-Olmo D., Garcia-Arranz M., Garcia L.G., Cuellar E.S., Blanco I.F., Prianes L.A., et al. Autologous stem cell transplantation for treatment of rectovaginal fistula in perianal Crohn's disease: a new cell-based therapy. Int. J. Colorectal Dis. 2003, 18:451-454.
90. Garcia-Olmo D., Garcia-Arranz M., Herreros D., Pascual I., Peiro C., Rodriguez-Montes J.A. A phase I clinical trial of the treatment of Crohn's fistula by adipose mesenchymal stem cell transplantation. Dis. Colon Rectum 2005, 48:1416-1423.
91. Garcia-Olmo D., Herreros D., Pascual I., Pascual J.A., Del-Valle E., Zorrilla J., et al. Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Dis. Colon Rectum 2009, 52:79-86.
92. Garcia-Arranz M., Gomez-Pinedo U., Hardisson D., Herreros D., Guadalajara H., Garcia-Gomez I., et al. Histopathological analysis of human specimens removed from the injection area of expanded adipose-derived stem cells. Histopathology 2010, 56:979-982.
93. Herreros M.D., Garcia-Arranz M., Guadalajara H., De-La-Quintana P., Garcia-Olmo D., Group F.C. Autologous expanded adipose-derived stem cells for the treatment of complex cryptoglandular perianal fistulas: a phase III randomized clinical trial (FATT 1: fistula advanced therapy trial 1) and long-term evaluation. Dis. Colon Rectum 2012, 55:762-772.
94. de la Portilla F., Alba F., Garcia-Olmo D., Herrerias J.M., Gonzalez F.X., Galindo A. Expanded allogeneic adipose-derived stem cells (eASCs) for the treatment of complex perianal fistula in Crohn's disease: results from a multicenter phase I/IIa clinical trial. Int. J. Colorectal Dis. 2013, 28:313-323.
95. Cho Y.B., Lee W.Y., Park K.J., Kim M., Yoo H.W., Yu C.S. Autologous adipose tissue-derived stem cells for the treatment of Crohn's fistula: a phase I clinical study. Cell Transplant. 2013, 22:279-285.
96. Lee W.Y., Park K.J., Cho Y.B., Yoon S.N., Song K.H., Kim do S., et al. Autologous adipose tissue-derived stem cells treatment demonstrated favorable and sustainable therapeutic effect for Crohn's fistula. Stem Cells 2013, 31:2575-2581.
97. TiGenix SAU, Cellerix Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease 2016.
98. Ciccocioppo R., Bernardo M.E., Sgarella A., Maccario R., Avanzini M.A., Ubezio C., et al. Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn's disease. Gut 2011, 60:788-798.
99. Guadalajara H., Herreros D., De-La-Quintana P., Trebol J., Garcia-Arranz M., Garcia-Olmo D. Long-term follow-up of patients undergoing adipose-derived adult stem cell administration to treat complex perianal fistulas. Int. J. Colorectal Dis. 2012, 27:595-600.
100. Lalu M.M., McIntyre L., Pugliese C., Fergusson D., Winston B.W., Marshall J.C., et al. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. PLOS ONE 2012, 7:e47559.
101. Sivasubramaniyan K., Lehnen D., Ghazanfari R., Sobiesiak M., Harichandan A., Mortha E., et al. Phenotypic and functional heterogeneity of human bone marrow- and amnion-derived MSC subsets. Ann. N. Y. Acad. Sci. 2012, 1266:94-106.
102. Francois M., Copland I.B., Yuan S., Romieu-Mourez R., Waller E.K., Galipeau J. Cryopreserved mesenchymal stromal cells display impaired immunosuppressive properties as a result of heat-shock response and impaired interferon-gamma licensing. Cytotherapy 2012, 14:147-152.
103. Moll G., Alm J.J., Davies L.C., von Bahr L., Heldring N., Stenbeck-Funke L., et al. Do cryopreserved mesenchymal stromal cells display impaired immunomodulatory and therapeutic properties?. Stem Cells 2014, 32:2430-2442.
104. Bernardo M.E., Avanzini M.A., Ciccocioppo R., Perotti C., Cometa A.M., Moretta A., et al. Phenotypical/functional characterization of in vitro-expanded mesenchymal stromal cells from patients with Crohn's disease. Cytotherapy 2009, 11:825-836.
105. Scharl M., Rogler G. Inflammatory bowel disease: dysfunction of autophagy?. Dig. Dis. 2012, 30(Suppl. 3):12-19.
106. Kim H.S., Shin T.H., Lee B.C., Yu K.R., Seo Y., Lee S., et al. Human umbilical cord blood mesenchymal stem cells reduce colitis in mice by activating NOD2 signaling to COX2. Gastroenterology 2013, 145. 1392-1403 e1391-1398.
107. Le Blanc K., Frassoni F., Ball L., Locatelli F., Roelofs H., Lewis I., et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008, 371:1579-1586.
108. Sun L., Wang D., Liang J., Zhang H., Feng X., Wang H., et al. Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus. Arthritis Rheum. 2010, 62:2467-2475.
109. Polchert D., Sobinsky J., Douglas G., Kidd M., Moadsiri A., Reina E., et al. IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Eur. J. Immunol. 2008, 38:1745-1755.
110. Taddio A., Tommasini A., Valencic E., Biagi E., Decorti G., De Iudicibus S., et al. Failure of interferon-gamma pre-treated mesenchymal stem cell treatment in a patient with Crohn's disease. World J. Gastroenterol. 2015, 21:4379-4384.
111. Duijvestein M., Molendijk I., Roelofs H., Vos A.C., Verhaar A.P., Reinders M.E., et al. Mesenchymal stromal cell function is not affected by drugs used in the treatment of inflammatory bowel disease. Cytotherapy 2011, 13:1066-1073.
112. Chen X., Gan Y., Li W., Su J., Zhang Y., Huang Y., et al. The interaction between mesenchymal stem cells and steroids during inflammation. Cell Death Dis. 2014, 5:e1009.
113. Barbash I.M., Chouraqui P., Baron J., Feinberg M.S., Etzion S., Tessone A., et al. Systemic delivery of bone marrow-derived mesenchymal stem cells to the infarcted myocardium: feasibility, cell migration, and body distribution. Circulation 2003, 108:863-868.
114. Dinesen L., Wang A., Vianello F., Tait P., Leen E., Davis J., et al. Mesenchymal stem cells administered via novel selective mesenteric artery cannulation for the treatment of severe refractory Crohn's disease. 4th Conference of ESCO 2009.
115. Zhang J., Gong J.F., Zhang W., Zhu W.M., Li J.S. Effects of transplanted bone marrow mesenchymal stem cells on the irradiated intestine of mice. J. Biomed. Sci. 2008, 15:585-594.
116. Ko I.K., Kim B.G., Awadallah A., Mikulan J., Lin P., Letterio J.J., et al. Targeting improves MSC treatment of inflammatory bowel disease. Mol. Ther.: J. Am. Soc. Gene Ther. 2010, 18:1365-1372.
117. Colletti E., El Shabrawy D., Soland M., Yamagami T., Mokhtari S., Osborne C., et al. EphB2 isolates a human marrow stromal cell subpopulation with enhanced ability to contribute to the resident intestinal cellular pool. FASEB J.: Off. Publ. Fed. Am. Soc. Exp. Biol. 2013, 27:2111-2121.
118. Levy O., Zhao W., Mortensen L.J., Leblanc S., Tsang K., Fu M., et al. mRNA-engineered mesenchymal stem cells for targeted delivery of interleukin-10 to sites of inflammation. Blood 2013, 122:e23-e32.